INTRODUCTION
Fibromyalgia (FM) is a common chronic pain condition with multiple associated symptom domains. While FM is diagnosed based on the presence of chronic pain and tenderness [1] , patients also frequently experience other symptoms, including fatigue, poor sleep, anxiety, and depression [2] . Three medications (duloxetine [3] , milnacipran [4] , and pregabalin [5] 
IMMPACT RECOMMENDATIONS AND USE OF PATIENT RESPONSE THRESHOLDS TO DETERMINE CLINICAL RELEVANCE
The initiative on methods, measurement, and pain assessment in clinical trials (IMMPACT) has recommended classifying pain responses in chronic pain patients as minimally important (10-20% pain reduction from baseline), moderately important (C30%), and substantial (C50%), based on three chronic pain studies that assessed changes in pain scores (on a numerical rating scale from 0 to 10) along with patient impressions of overall improvement [42] . A threshold of 30% change from baseline in the Brief Pain Inventory average pain and severity scores has been confirmed in a recent study as a minimally clinically relevant response in an FM population [43] . Responder analysis is a useful way to complement and supplement an analysis based on means, and has been recommended by regulatory bodies as a way to establish clinically relevant benefits [44, 45] . Responder analysis can also be extended to show the cumulative proportion of responders and of all patients over a range of possible cutoff points [44, 46, 47] [52] . We suggest that all potential effects of an intervention, benefits, and harms, should be considered when evaluating the net clinical benefit, particularly for a condition such as FM. This assessment should also take into account the potential for adverse events, contraindications, and patient comorbid conditions. The most common adverse reactions to these medications (occurring in at least 5% of treated patients and at least twice the incidence of placebo patients) are nausea, dry mouth, somnolence, constipation, decreased appetite, and hyperhidrosis for duloxetine [3] ; nausea, headache, constipation, dizziness, insomnia, hot flush, hyperhidrosis, vomiting, palpitations, increased heart rate, dry mouth, and hypertension for milnacipran [4] ; and dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and abnormal thinking (primarily difficulty with concentration or attention) for pregabalin [5] . All three medications were generally well tolerated in clinical trials of patients with FM, with the majority of patients successfully completing the trials [3] [4] [5] . [53] , hydrotherapy [54] , and cognitivebehavioral therapy [55] . Multi-modal treatment, including at least one educational treatment and one exercise therapy, has also been shown to have short-term benefits [56] . While it may not be feasible for trials of non-pharmacological therapies to achieve the same high methodological and regulatory standards as trials of pharmacological therapies (for instance, in exercise trials it is not possible to blind participants to their treatment), we believe that the points raised in this commentary could be also worthy of consideration for trials of nonpharmacological interventions. 
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